[go: up one dir, main page]

BRPI0414236A - forma hidratada cristalina do composto, composição farmacêutica, processos para formação de um composto, para a manufatura de uma forma cristalina, e de uma composição farmacêutica, uso de uma forma cristalina, e, método de tratar uma condição de enfermidade - Google Patents

forma hidratada cristalina do composto, composição farmacêutica, processos para formação de um composto, para a manufatura de uma forma cristalina, e de uma composição farmacêutica, uso de uma forma cristalina, e, método de tratar uma condição de enfermidade

Info

Publication number
BRPI0414236A
BRPI0414236A BRPI0414236-5A BRPI0414236A BRPI0414236A BR PI0414236 A BRPI0414236 A BR PI0414236A BR PI0414236 A BRPI0414236 A BR PI0414236A BR PI0414236 A BRPI0414236 A BR PI0414236A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
crystalline
processes
crystalline form
Prior art date
Application number
BRPI0414236-5A
Other languages
English (en)
Inventor
Rebecca Jane Booth
Peter Anthony Cittern
Jeffrey Norman Crabb
John Horbury
David Wyn Calvert Jones
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414236(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0321127A external-priority patent/GB0321127D0/en
Priority claimed from GB0404859A external-priority patent/GB0404859D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of BRPI0414236A publication Critical patent/BRPI0414236A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMA HIDRATADA CRISTALINA DO COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSOS PARA FORMAçãO DE UM COMPOSTO, PARA A MANUFATURA DE UMA FORMA CRISTALINA, E DE UMA COMPOSIçãO FARMACêUTICA, USO DE UMA FORMA CRISTALINA, E, MéTODO DE TRATAR UMA CONDIçãO DE ENFERMIDADE". São descritas duas formas poliméricas de sal de cálcio do ácido bis ¢(E)-7-¢4-(4-fluorofenil)-6-isopropil-2-¢metil(metilsulfonil)amino! pirimidin-5-il!(3R,5S)-3,5-diidroxiept-6-enóico!, processos para produzi-las e seu uso como inibidores da HMG Co-A redutase.
BRPI0414236-5A 2003-09-10 2004-09-08 forma hidratada cristalina do composto, composição farmacêutica, processos para formação de um composto, para a manufatura de uma forma cristalina, e de uma composição farmacêutica, uso de uma forma cristalina, e, método de tratar uma condição de enfermidade BRPI0414236A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0321127A GB0321127D0 (en) 2003-09-10 2003-09-10 Chemical compounds
GB0404859A GB0404859D0 (en) 2004-03-04 2004-03-04 Chemical compound
PCT/GB2004/003829 WO2005023779A1 (en) 2003-09-10 2004-09-08 Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6 -enoicacid] calcium salt

Publications (1)

Publication Number Publication Date
BRPI0414236A true BRPI0414236A (pt) 2006-10-31

Family

ID=34276833

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414236-5A BRPI0414236A (pt) 2003-09-10 2004-09-08 forma hidratada cristalina do composto, composição farmacêutica, processos para formação de um composto, para a manufatura de uma forma cristalina, e de uma composição farmacêutica, uso de uma forma cristalina, e, método de tratar uma condição de enfermidade

Country Status (31)

Country Link
US (4) US20060293355A1 (pt)
EP (1) EP1663989B1 (pt)
JP (1) JP2007505090A (pt)
KR (1) KR20070019943A (pt)
CN (1) CN1878760B (pt)
AR (1) AR045628A1 (pt)
AT (1) ATE428701T1 (pt)
AU (1) AU2004270467B8 (pt)
BR (1) BRPI0414236A (pt)
CA (1) CA2537962C (pt)
CO (1) CO5670355A2 (pt)
CY (1) CY1109173T1 (pt)
DE (1) DE602004020640D1 (pt)
DK (1) DK1663989T3 (pt)
ES (1) ES2324042T3 (pt)
HR (1) HRP20090335T1 (pt)
IL (1) IL174073A (pt)
IS (1) IS2689B (pt)
MX (1) MXPA06002761A (pt)
MY (1) MY142615A (pt)
NO (1) NO336358B1 (pt)
NZ (1) NZ545785A (pt)
PL (1) PL1663989T3 (pt)
PT (1) PT1663989E (pt)
RU (1) RU2363697C2 (pt)
SA (1) SA04250297B1 (pt)
SI (1) SI1663989T1 (pt)
TW (1) TWI370817B (pt)
UA (1) UA85062C2 (pt)
UY (1) UY28501A1 (pt)
WO (1) WO2005023779A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
CN1301977C (zh) 2001-07-13 2007-02-28 阿斯特拉曾尼卡英国有限公司 氨基嘧啶化合物的制备方法
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
JP4579821B2 (ja) 2002-12-16 2010-11-10 アストラゼネカ・ユーケイ・リミテッド ピリミジン化合物を製造するための方法
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
BRPI0706062A2 (pt) * 2006-09-18 2011-03-22 Teva Pharma rosuvastatina cálcica cristalina
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
SI2752407T1 (sl) * 2009-01-14 2016-07-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalni kalcijev rosuvastatin trihidrat
MX2011007478A (es) * 2009-01-15 2011-09-15 Sag Egis Gyogyszergyar Nylvanosan Muekoedoe Reszvenytarsa Proceso para la preparacion de sales de rosuvastatina.
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
WO2011074016A1 (en) 2009-12-17 2011-06-23 Matrix Laboratories Ltd Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
WO2012069394A1 (en) 2010-11-22 2012-05-31 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
EP2699552A1 (en) 2011-04-18 2014-02-26 Basf Se Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
WO2014050874A1 (ja) * 2012-09-27 2014-04-03 東和薬品株式会社 ロスバスタチンカルシウムの新規結晶形態およびその製造方法
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
EP3103878A4 (en) 2014-02-06 2017-08-16 API Corporation Rosuvastatin calcium and process for producing intermediate thereof
HUE061878T2 (hu) * 2016-04-18 2023-08-28 Morepen Laboratories Ltd A kristályos rozuvasztatin kalcium új polimorf formája és új eljárások a kristályos és amorf rozuvasztatin kalcium elõállítására
CN105837516B (zh) * 2016-05-16 2018-07-10 山东新时代药业有限公司 一种瑞舒伐他汀钙晶型及其制备方法
US11446757B2 (en) 2017-09-13 2022-09-20 Jfe Steel Corporation Double-sided friction stir welding method for metal sheets and double-sided friction stir welding device
WO2024157513A1 (ja) 2023-01-25 2024-08-02 Ｊｆｅスチール株式会社 テーラードブランク材、ならびに、テーラードブランク材の製造方法および製造設備

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) * 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
WO1990003973A1 (en) 1988-10-06 1990-04-19 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) * 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
DK0577040T3 (da) * 1992-07-02 1998-02-02 Hoechst Ag Fremgangsmåde til fremstilling af (3R,5S)6-hydroxy-3,,5-O-isopropyliden-3,5-dihydroxyhexansyre-tert.-butylester
ES2167587T3 (es) 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).
US6278001B1 (en) * 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
DE69719755T2 (de) 1996-06-24 2003-11-20 Novartis Ag, Basel Polymorphe verbindungen
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
ES2234323T3 (es) * 1998-12-10 2005-06-16 Kaneka Corporation Procedimiento para producir un precursor de simvastatina.
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
AU7717500A (en) 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
EP1535613B1 (en) 1999-11-17 2010-08-25 Teva Pharmaceutical Industries, Ltd. Process for preparing a polymorphic form of atorvastatin calcium
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
HRP20030347A2 (en) 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
AU3289102A (en) 2000-11-16 2002-06-11 Teva Pharma Hydrolysis of (R(R*,R*))-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (pt) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
WO2002098854A2 (en) 2001-06-06 2002-12-12 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
CN1301977C (zh) * 2001-07-13 2007-02-28 阿斯特拉曾尼卡英国有限公司 氨基嘧啶化合物的制备方法
NZ529913A (en) 2001-08-16 2005-03-24 Teva Pharma Processes for preparing calcium salt forms of statins
JP2005503393A (ja) 2001-08-22 2005-02-03 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド インドール誘導体の製造方法
CA2459926A1 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
US20050222415A1 (en) 2002-05-21 2005-10-06 Yatendra Kumar Process for the preparation of rosuvastatin
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
JP4579821B2 (ja) * 2002-12-16 2010-11-10 アストラゼネカ・ユーケイ・リミテッド ピリミジン化合物を製造するための方法
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US7161004B2 (en) * 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
BRPI0611707A2 (pt) 2005-06-29 2012-04-24 Compumedics Ltd conjunto de sensor com ponte condutiva
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
AU2004270467A1 (en) 2005-03-17
TW200526595A (en) 2005-08-16
CY1109173T1 (el) 2014-07-02
WO2005023779A1 (en) 2005-03-17
NZ545785A (en) 2010-03-26
US20100222373A1 (en) 2010-09-02
RU2363697C2 (ru) 2009-08-10
IL174073A0 (en) 2006-08-01
NO336358B1 (no) 2015-08-03
NO20061181L (no) 2006-03-29
IS8385A (is) 2006-03-30
IS2689B (is) 2010-10-15
DK1663989T3 (da) 2009-07-06
SI1663989T1 (sl) 2009-08-31
US20060293355A1 (en) 2006-12-28
MY142615A (en) 2010-12-15
SA04250297B1 (ar) 2008-11-18
ATE428701T1 (de) 2009-05-15
PT1663989E (pt) 2009-06-09
AU2004270467B8 (en) 2008-09-18
CN1878760B (zh) 2011-11-09
JP2007505090A (ja) 2007-03-08
CN1878760A (zh) 2006-12-13
CA2537962A1 (en) 2005-03-17
CO5670355A2 (es) 2006-08-31
US20120059022A1 (en) 2012-03-08
CA2537962C (en) 2012-10-23
RU2006111354A (ru) 2007-10-27
US8436167B2 (en) 2013-05-07
UY28501A1 (es) 2005-04-29
KR20070019943A (ko) 2007-02-16
AU2004270467B2 (en) 2008-08-21
IL174073A (en) 2014-03-31
US20130225622A1 (en) 2013-08-29
HK1090361A1 (en) 2006-12-22
UA85062C2 (uk) 2008-12-25
AR045628A1 (es) 2005-11-02
HRP20090335T1 (hr) 2009-07-31
MXPA06002761A (es) 2006-12-14
EP1663989B1 (en) 2009-04-15
PL1663989T3 (pl) 2009-08-31
ES2324042T3 (es) 2009-07-29
TWI370817B (en) 2012-08-21
EP1663989A1 (en) 2006-06-07
DE602004020640D1 (de) 2009-05-28

Similar Documents

Publication Publication Date Title
BRPI0414236A (pt) forma hidratada cristalina do composto, composição farmacêutica, processos para formação de um composto, para a manufatura de uma forma cristalina, e de uma composição farmacêutica, uso de uma forma cristalina, e, método de tratar uma condição de enfermidade
CY1109756T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικα αλατα 7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2- [μεθυλ(μεθυλσουλφονυλ)αμινο] πυριμιδιν-5-υλ]-(3r,5s)-3,5-διυδροξυεπτ-6-ενοϊκου οξεος
UY28341A1 (es) Proceso químico
BRPI0414499A (pt) forma cristalina composição farmacêutica, processo para a fabricação de uma composição farmacêutica, uso de uma forma cristalina, método de tratamento de uma condição de enfermidade, e, processo para a fabricação de uma forma cristalina
ID29432A (id) Garam bis asam(e)-7- 4-(4-fluorofenil)-6-isopropil-2-metil (metilsulfonil)amino pirimidin-5-il (3r,5s)-3,5-dihidroksihept-6-enoat kalsium kristalin
SI1682536T1 (sl) Postopek izdelave kalcijeve soli rosuvastatin-(E)-7-(4-(4-fluorofenil) -6-izopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il) (3r,5s)-3,5- dihidroksihept-6-enojske kisline in njenih kristalnih vmesnih spojin
BRPI0412763A (pt) formas anidras, hidratadas ou solvatadas de um composto, forma cristalina, composição farmacêutica, e, método para o tratamento ou a profilaxia de distúrbios
UY27567A1 (es) Compuestos cristalinos novedosos
MY134902A (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
MX2020013896A (es) Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
BRPI0514741A (pt) derivados de hexahidro-pirazino[1, 2-a]pirimidina-4, 7-diona substituìdos por aminoácidos
AR054252A1 (es) Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina
PT1632232E (pt) Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
ATE553098T1 (de) Verfahren zur herstellung von rosuvastatin- calcium
IL181649A0 (en) Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino) benzonitrile
SG155885A1 (en) Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
EA200800392A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
UY27271A1 (es) Composiciones farmacéuticas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]